Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Pancreatic Neoplasms 11Colorectal Neoplasms 10Neoplasm Metastasis 6Rhabdomyosarcoma 3Neuroblastoma 3Lung Neoplasms 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma, Ewing 2Sarcoma 2Rectal Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Neuroendocrine 2Biliary Tract Neoplasms 2Uterine Cervical Neoplasms 1Solid Tumors 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Refractory Solid Tumors 1Pancreatic Ductal Adenocarcinoma 1Ovarian Neoplasms 1Medulloblastoma 1Malignant mesenchymal tumor 1Intestinal Neoplasms 1Gastrointestinal Neoplasms 1

Interventions

atezolizumab 2tocilizumab 1spartalizumab 1pembrolizumab 1fludarabine phosphate 1fludarabine 1adagrasib 1Trastuzumab 1Pemetrexed 1Oxaliplatin 1Nivolumab 1Leucovorin 1Irinotecan 1Fluorouracil 1Docetaxel 1Cyclophosphamide 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumors × Irinotecan × 30 days × Clear all
NCT07415031 2026-05-15

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Mirati Therapeutics Inc.

Phase 2 Recruiting
170 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡